Zheng Qingyuan, Yu Xiao, Zhang Menggang, Zhang Shuijun, Guo Wenzhi, He Yuting
Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Key Laboratory of Hepatobiliary and Pancreatic Surgery and Digestive Organ Transplantation of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Front Cell Dev Biol. 2021 Dec 20;9:750084. doi: 10.3389/fcell.2021.750084. eCollection 2021.
Long non-coding RNAs (lncRNA), as key regulators of cell proliferation and death, are involved in the regulation of various processes in the nucleus and cytoplasm, involving biological developmental processes in the fields of immunology, neurobiology, cancer, and stress. There is great scientific interest in exploring the relationship between lncRNA and tumors. Many researches revealed that lymph enhancer-binding factor 1-antisense RNA 1 (LEF1-AS1), a recently discovered lncRNA, is downregulated in myeloid malignancy, acting mainly as a tumor suppressor, while it is highly expressed and carcinogenic in glioblastoma (GBM), lung cancer, hepatocellular carcinoma (HCC), osteosarcoma, colorectal cancer (CRC), oral squamous cell carcinoma (OSCC), prostatic carcinoma, retinoblastoma, and other malignant tumors. Furthermore, abnormal LEF1-AS1 expression was associated with tumorigenesis, development, survival, and prognosis via the regulation of target genes and signaling pathways. This review summarizes the existing data on the expression, functions, underlying mechanism, relevant signaling pathways, and clinical significance of LEF1-AS1 in cancer. It is concluded that LEF1-AS1 can serve as a novel biomarker for the diagnosis and prognosis of various tumors, thus deserves further attention in the future.
长链非编码RNA（lncRNA）作为细胞增殖和死亡的关键调节因子，参与细胞核和细胞质中各种过程的调控，涉及免疫学、神经生物学、癌症和应激等领域的生物发育过程。探索lncRNA与肿瘤之间的关系具有极大的科学意义。许多研究表明，淋巴增强因子1反义RNA 1（LEF1-AS1）是一种最近发现的lncRNA，在髓系恶性肿瘤中表达下调，主要起肿瘤抑制作用，而在胶质母细胞瘤（GBM）、肺癌、肝细胞癌（HCC）、骨肉瘤、结直肠癌（CRC）、口腔鳞状细胞癌（OSCC）、前列腺癌、视网膜母细胞瘤和其他恶性肿瘤中高表达且具有致癌性。此外，LEF1-AS1的异常表达通过调控靶基因和信号通路与肿瘤发生、发展、生存及预后相关。本综述总结了关于LEF1-AS1在癌症中的表达、功能、潜在机制、相关信号通路及临床意义的现有数据。得出结论，LEF1-AS1可作为各种肿瘤诊断和预后的新型生物标志物，因此在未来值得进一步关注。
